Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

AMSBIO has announced a new PD-1 (Programmed Death) inhibitor screening assay kit for cancer research studies. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but is already planning a move the drug into the first-line setting.

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.